SpectraCure’s MSEK 140 rights issue of units is fully guaranteed
THIS PRESS RELEASE MAY NOT BE ANNOUNCED, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES, JAPAN, CANADA OR ANY OTHER JURISDICTION WHERE SUCH PUBLICATION OR DISTRIBUTION WOULD VIOLATE APPLICABLE LAWS OR RULES OR WOULD REQUIRE ADDITIONAL REGISTRATION OR OTHER ACTION. A top guarantee up to 100 percent of the rights issue has been […]
SpectraCure AB Quarterly Report (1 Jan to 31 March) 2020
Please note that the attached report is in Swedish. First quarter 2020 The figures for 2020 and 2019 refer to the Group. Other operating income amounted to SEK 1,185 (650) thousand Profit after tax amounted to SEK -3,784 (-2,776) thousand Earnings per share before and after dilution: SEK -0.04 (-0.03) Cash flow from operating activities […]
Patent application enters PCT phase, SpectraCure ensures development and work
SpectraCure’s work and development proceeds with several parallel projects. A patent application which covers a new technology that improves upon the Company’s IDOSE technology is now progressing to the so-called PCT phase, which is a way of coordinating patent applications in all the countries of the world. This is a result of the positive outcome […]
New study underway in the US and approval from the Food and Drug Administration (FDA)
The meeting between SpectraCure and Memorial Sloan Kettering Cancer Center in New York, USA, was held as scheduled on Friday. As previously announced, it was a formal meeting for the start-up and review of routines and equipment. – I am very excited about the study and look forward to start patient recruitment, says James A. Eastham, Chief of the Urology Service at Memorial Sloan […]
The meeting between SpectraCure and Memorial Sloan Kettering Cancer Center in New York, USA takes place tomorrow, March 13 2020
Refers to the latest travel information regarding the United States. The scheduled meeting, "Site Initiation Visit", between SpectraCure and Memorial Sloan Kettering Cancer Center in New York, USA, will be conducted tomorrow Friday. It is a formal meeting for the start-up and review of procedures and equipment. After the meeting is completed, the study is underway and recruitment of […]
Agreement reached between SpectraCure and one more hospital – Memorial Sloan Kettering Cancer Center i n New York
SpectraCure AB (publ) and Memorial Sloan Kettering Cancer Center in New York, USA, have today signed an agreement, which means that the hospital will be the fourth hospital in SpectraCure's clinical program. A formal meeting ("Site Initiation Visit") for the start-up and review of routines and equipment will be arranged between the company and the […]
Year End Report 2019
Fourth quarter (1 October – 31 December 2019) Other income amounted to TSEK 1 243 (TSEK 197). Profit after tax amounted to TSEK -3 706 (-3 242). Corresponding to SEK -0,04 (-0,05) per share before and after diluted earnings. Operating cash flow was TSEK -3 407 (-3 806). Full year 2019 Other income amounted to TSEK 3 248 (1 […]
Reinforcements in SpectraCure’s organization
Today we are welcoming Johan Glindre to SpectraCure. Johan Glindre will be working as a Clinical Project Leader and has a solid background in clinical studies, project management and quality work. Johan holds a Master of Molecular Biology from Lund University, and has among other things, been working for Pharmacia and OctaPharma with quality work […]
A welcome addition to support our ongoing product development. SpectraCure receives research contribution from the EU.
SpectraCure (http://www.SpectraCure.com)has been awarded with funds from the EU which strengthens the research within the company’s technology, to treat prostate cancer with SpectraCure’s IDOSE dose platform and focal PDT treatment (PDT). The funding enables the employment of a young researcher for four years. The funding is part of an Innovative Training Network where SpectraCure participates […]
Exercise rate of 98.8 percent for SpectraCure’s warrants (TO3)
On 29 November, SpectraCure AB (publ) (“SpectraCure”) ended the exercise period for the Series 3 TO3 B subscription warrants. In total, 5,828,739 shares have been subscribed during the now concluded exercise period. SpectraCure is thus provided MSEK 37.9 in proceeds, before issuance costs to the estimated amount of MSEK 1.1. The exercise rate was 98.8 percent. As […]
